Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

3 recruiting2 with results

Enrollment Performance

Analytics

N/A
5(83.3%)
Phase 2
1(16.7%)
6Total
N/A(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05641844Not ApplicableRecruiting

A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal Fistulas

Role: lead

NCT04699305Recruiting

Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers

Role: lead

NCT04577183Not ApplicableTerminated

A Prospective, Open Label, Multicenter Trial for Evaluating the Efficacy of Treating and Managing Wounds in Elderly Population in Specialized Nursing Facilities Using RD1

Role: lead

NCT04899466Not ApplicableRecruiting

Efficacy Evaluation of ActiGraft in Secondary Closure of Abdominal Surgical Wound Dehiscence

Role: lead

NCT04745806Not ApplicableTerminated

Post Marketing Trial for Evaluating the Effectiveness of ActiGraft in Treating Lower Extremity Hard To Heal Wounds

Role: lead

NCT04185558Not ApplicableCompleted

Safety and Efficacy of ActiGraft Pro Compared to Standard of Care in DFUs

Role: lead

NCT01396837Phase 2Completed

Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.

Role: lead

All 7 trials loaded